# Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

Source: https://onco.cc/trials/nct05797831/  
OnCo record `nct05797831` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of KRT-232 in endometrial cancer, run by Kartos Therapeutics, Inc., now recruiting.

## Summary

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer is a phase 2/3 interventional study registered as NCT05797831 by Kartos Therapeutics, Inc., with 268 participants planned, started 2023-07-17 and due to reach its primary completion in 2025-08. Interventions recorded: Navtemadlin, Navtemadlin Placebo. Conditions listed: Endometrial Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05797831
- Phase: 2/3
- Setting: A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects With TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy
- Sponsor: Kartos Therapeutics, Inc.
- Enrolled: 268

## Sources

- ClinicalTrials.gov NCT05797831: https://clinicaltrials.gov/study/NCT05797831

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/)
- drugs: [KRT-232](https://onco.cc/drugs/krt-232/)
- companies: [Kartos Therapeutics](https://onco.cc/companies/kartos-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct05797831.json